The estimated Net Worth of Lisa Deschamps is at least $2.15 Million dollars as of 1 February 2022. Lisa Deschamps owns over 11,664 units of Verona Pharma Plc stock worth over $2,120,148 and over the last 4 years Lisa sold VRNA stock worth over $25,773.
Sign up
Lisa Deschamps VRNA stock SEC Form 4 insiders trading
Lisa has made over 3 trades of the Verona Pharma Plc stock since 2021, according to the Form 4 filled with the SEC. Most recently Lisa sold 11,664 units of VRNA stock worth $9,098 on 1 February 2022.
The largest trade Lisa's ever made was selling 11,672 units of Verona Pharma Plc stock on 2 November 2021 worth over $7,704. On average, Lisa trades about 3,780 units every 30 days since 2021. As of 1 February 2022 Lisa still owns at least 70,320 units of Verona Pharma Plc stock.
You can see the complete history of Lisa Deschamps stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Lisa Deschamps's mailing address?
Lisa's mailing address filed with the SEC is 3 MORE LONDON RIVERSIDE, , LONDON, X0, SE1 2RE.
Insiders trading at Verona Pharma Plc
Over the last 4 years, insiders at Verona Pharma Plc have traded over $308,854,297 worth of Verona Pharma Plc stock and bought 5,029,736 units worth $6,770,194 . The most active insiders traders include Andrew Sinclair, Advisors Llc Orbi Med Capit..., and Rishi Gupta. On average, Verona Pharma Plc executives and independent directors trade stock every 18 days with the average trade being worth of $11,234,071. The most recent stock trade was executed by David Zaccardelli on 12 August 2024, trading 400,000 units of VRNA stock currently worth $1,280,000.
What does Verona Pharma Plc do?
verona pharma is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. we are currently focused on developing our novel lead therapeutic candidate in the treatment of chronic obstructive pulmonary fibrosis (copd) and cystic fibrosis (cf), and may expand our pipeline to help address the gaps in treatment of other respiratory diseases. we are led by a team with deep industry experience, including extensive backgrounds in the discovery, development and commercialization of respiratory therapies. in addition, we have established relationships with leading research institutions and advocacy organizations in the respiratory space and have received awards in support of our continued work and innovation. verona pharma is listed on the nasdaq global market in the united states under the ticker symbol vrna and on the london stock exchange in the united kin
What does Verona Pharma Plc's logo look like?
Complete history of Lisa Deschamps stock trades at Verona Pharma Plc
Verona Pharma Plc executives and stock owners
Verona Pharma Plc executives and other stock owners filed with the SEC include:
-
Dr. Kathleen A. Rickard,
Chief Medical Officer -
Dr. David S. Zaccardelli,
Pres, CEO & Exec. Director -
Mark W. Hahn,
Chief Financial Officer -
Ostra Jewell,
Sr. VP of HR -
Matthew Casbon,
VP of Sales, Marketing & Training -
Dr. Tara Rheault M.P.H., Ph.D.,
Sr. VP of R&D -
Christopher Martin,
VP of Commercial -
Benjamin Harber,
Company Sec. -
Caroline Diaz,
Sr. VP of Regulatory Affairs -
Ben Harber,
Company Sec. -
Nina Church,
Exec. Director of Global Clinical Devel. -
Dr. Peter Spargo,
Sr. VP of Chemistry Manufacturing & Controls -
Victoria Stewart,
Director of Communications -
Dr. Kathleen Rickard,
Chief Medical Officer -
Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIA,
Gen. Counsel -
Industries Holdings Llcai B...,
-
Martin Edwards,
Director -
Vikas Sinha,
Director -
Christina Ackermann,
Director -
Mark W Hahn,
Chief Financial Officer -
David Zaccardelli,
President and CEO -
Advisors Llc Orbi Med Capit...,
-
Kenneth Cunningham,
Director -
Anders Ullman,
Director -
David R Ebsworth,
Director -
Lisa Deschamps,
Director -
Claire Poll,
General Counsel -
Kathleen A. Rickard,
Chief Medical Officer -
Andrew Sinclair,
Director -
Rishi Gupta,
Director -
Michael Austwick,
Director -
James Aloysius Brady,
Director -
Andrew Fisher,
General Counsel